Side-by-side · Research reference
HumaninvsPTD-DBM
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED14/52 cited
BAnimal-StrongHUMAN-REVIEWED10/40 cited
Humanin
Mitochondrial-Derived Peptide · Cytoprotective
SQ · Experimental
01Mechanism of Action
Parameter
Humanin
PTD-DBM
Primary target
Intracellular: Bax, Bim, tBid (pro-apoptotic Bcl-2 family). Extracellular: FPRL1/2 G-protein-coupled receptorsZhu 2022Lue 2021
CXXC5–Dishevelled protein-protein interaction
Pathway
Humanin binds Bax/Bim → inhibits mitochondrial outer membrane permeabilization (MOMP) → blocks cytochrome c release → prevents caspase activation → cell survival
Downstream effect
Suppression of apoptosis, mitochondrial stabilization, reduced oxidative stress, preservation of germ cells and neurons under stressZhu 2022Lue 2021Velentza 2024
Activated Wnt/β-catenin signaling promotes hair follicle regeneration, dermal stem cell activation, reduced myofibroblast differentiation
Feedback intact?
Not applicable — peptide acts as anti-apoptotic signal, not hormonal axis
Not applicable — pathway derepression rather than receptor agonism
Origin
Encoded by short open reading frame in mitochondrial 16S rRNA gene (MTRNR2). 24-28 amino acids. 13 homologous variants (MTRNR2L1-L13) identified.Zhu 2022Shahzaib 2026
Engineered fusion: cell-penetrating PTD sequence + Dvl-binding motif targeting CXXC5
Antibody development
Not reported in animal models
—
02Dosage Protocols
Parameter
Humanin
PTD-DBM
Standard experimental dose (HNG)
4 mg/kg IP (rat)
Most common dose in rodent models.
—
Ex vivo bone culture
1 µg/mL
Protective against venetoclax-induced bone growth retardation.
—
Frequency
Daily (IP)
—
Duration
8–12 weeks in animal studies
—
Human data
None — no clinical trials reported
—
Analog (HNG)
Gly[14]-humanin — more potent variant
Substitution at position 14 enhances cytoprotective activity.
—
Wound healing protocol
—
Hydrogel patch delivery (concentration not disclosed)
Pyrogallol-HA patch, murine model.
Hair regeneration protocol
—
Topical application (exact dose not disclosed)
Wound-induced hair neogenesis model, mice.
Co-administration
—
Valproic acid (GSK-3β inhibitor) for wound healing synergyLee 2023
Combined treatment maximized scar reduction.
Human translation
—
No published human studies
03Metabolic / Fat Loss Evidence
Parameter
Humanin
PTD-DBM
Direct fat loss evidence
None
—
Mechanism overlap
Mitochondrial health may indirectly influence metabolic efficiency, but no quantified effect
—
04Side Effects & Safety
Parameter
Humanin
PTD-DBM
Animal model safety
Well-tolerated in rat and mouse studies at 4 mg/kg for 8–12 weeks
—
Human safety data
None — no clinical trials
—
Theoretical fibrillation risk
Induces amyloid-like fibrillation of Bax/BID. Long-term sequelae unknown.
—
Injection site reaction
Not reported in animal studies (IP route)
—
Reproductive safety
Protective in POI model (cyclophosphamide-induced), no adverse effects on fertility notedHuang 2025
—
Reported adverse events
—
None reported in animal studies
Wnt pathway activation risks
—
Theoretical risk of aberrant proliferation; Wnt dysregulation linked to tumorigenesis
Long-term safety
—
Unknown — no chronic dosing or human data
Delivery vehicle effects
—
HA-PG hydrogel well-tolerated in mice; human translation pending
Absolute Contraindications
Humanin
- ·Unknown — no human data
PTD-DBM
- ·Active malignancy (Wnt pathway involvement in tumorigenesis)
- ·Pregnancy / lactation (no safety data)
Relative Contraindications
Humanin
- ·Active malignancy (theoretical risk of anti-apoptotic effect on tumour cells)
PTD-DBM
- ·History of Wnt-driven tumors
- ·Skin lesions with uncertain malignant potential
05Administration Protocol
Parameter
Humanin
PTD-DBM
1. Route (experimental)
Intraperitoneal (IP) in animal models. Subcutaneous route untested. No human protocols exist.
Pyrogallol-functionalized hyaluronic acid (HA-PG) hydrogel patch loaded with PTD-DBM peptide, applied directly to wound bed. Adhesive hydrogel provides sustained release over multiple days.Lee 2023
2. Reconstitution
Synthetic peptide reconstituted in sterile saline or PBS. No commercial formulation available.
Topical application to scalp or wound site. Precise formulation not disclosed; studies used Cxxc5 knockout or direct peptide application in wound-induced hair neogenesis models.Ryu 2023
3. Timing
Daily administration in animal studies. Optimal timing not characterized.
PTD-DBM + valproic acid (GSK-3β inhibitor) in HA-PG patch showed synergistic effect on scar reduction and regenerative wound healing. VPA enhances Wnt pathway activation downstream.Lee 2023
4. Storage
Lyophilised powder: -20 °C. Reconstituted: 4 °C, use within 7 days. Avoid freeze-thaw cycles.
Not disclosed in available literature. Peptide stability and storage conditions not published.
5. Human use
No FDA approval, no IND, no clinical trials. Experimental research tool only.
—
06Stack Synergy
Humanin
+ MOTS-c
Multi-pathwayBoth are mitochondrial-derived peptides. MOTS-c enhances metabolic efficiency and insulin sensitivity via AMPK activation, while humanin prevents mitochondrial apoptosis. Combined, they address mitochondrial function (MOTS-c) and survival signaling (humanin), supporting cellular resilience under metabolic and oxidative stress.
- Humanin
- 4 mg/kg IP · daily (animal model)
- MOTS-c
- 5 mg/kg IP · daily (animal model)
- Frequency
- Once daily
- Primary benefit
- Mitochondrial health, metabolic efficiency, anti-apoptotic signaling
PTD-DBM
— no documented stacks